Epstein-Barr virus immune response in high-risk nasopharyngeal carcinoma families in Greenland

2007 ◽  
Vol 79 (12) ◽  
pp. 1877-1881 ◽  
Author(s):  
Jeppe Friborg ◽  
Ruth F. Jarrett ◽  
Mei-Ying Liu ◽  
Kerstin I. Falk ◽  
Anders Koch ◽  
...  
Keyword(s):  
Immune Response ◽  
High Risk ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan

2004 ◽  
Vol 111 (1) ◽  
pp. 117-123 ◽  
Author(s):  
Amy Pickard ◽  
Chien-Jen Chen ◽  
Scott R. Diehl ◽  
Mei-Ying Liu ◽  
Yu-Juen Cheng ◽  
...  
Keyword(s):  
High Risk ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Epstein Barr

Epstein–Barr virus activation in Raji cells by extracts of preserved food from high risk areas for nasopharyngeal carcinoma

1988 ◽  
Vol 9 (8) ◽  
pp. 1455-1457 ◽  
Author(s):  
Y.M. Shao ◽  
A. Poirier ◽  
H. Ohshima ◽  
C. Malaveille ◽  
Y. Zeng ◽  
...  
Keyword(s):  
High Risk ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Raji Cells ◽  
Barr Virus ◽  
Risk Areas ◽  
Epstein Barr

scholarly journals Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jin-Hao Yang ◽  
Xue-Song Sun ◽  
Bei-Bei Xiao ◽  
Li-Ting Liu ◽  
Shan-Shan Guo ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
High Risk ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
De Novo ◽  
Intermediate Risk ◽  
Barr Virus ◽  
Metastatic Lesions ◽  
Ebv Dna ◽  
Epstein Barr

Abstract Background Nasopharyngeal carcinoma (NPC) is a malignancy predominantly associated with infection by the Epstein-Barr virus (EBV). Approximately 12,900 new cases of NPC occur each year, with more than 70% of cases occurring in the east and southeast Asia. NPC is different from ordinary head and neck squamous cell carcinoma due to its particular biological properties and it is highly sensitive to radiotherapy. With the development of RT technology, the 3-year local control rate and survival rates of non-metastatic NPC reached 80–90% in the intensity-modulated RT (IMRT) era. However, whether distant metastatic NPC (de novo mNPC, dmNPC) should receive locoregional RT (LRRT) needs to be clarified. Results Multivariate analysis identified three independent prognostic factors: Epstein-Barr virus (EBV) DNA, number of metastatic lesions, and number of metastatic organs. Through these factors, all patients were successfully divided into 3 subgroups: low-risk (single metastatic organ, EBV DNA ≤ 25,000 copies/ml, and ≤ 5 metastatic lesions), intermediate-risk (single metastatic organ, EBV DNA > 25,000 copies/ml, and ≤ 5 metastatic lesions), and high-risk (multiple metastatic organs or > 5 metastatic lesions or both). By comparing LRRT and non-LRRT groups, statistical differences were found in OS in the low-risk and intermediate-risk subgroups (p = 0.039 and p = 0.010, respectively) but no significant difference was found in OS in the high-risk subgroup (p = 0.076). Further multivariate analysis of different risk stratifications revealed that LRRT can improve OS of low- and intermediate-risk subgroups. Conclusions The risk stratification of dmNPC may be used as a new prognostic factor to help clinicians organize individualized LRRT treatment to improve the survival outcomes of dmNPC patients.

The immune response to terminal protein of Epstein-Barr virus in nasopharyngeal carcinoma patients

1995 ◽  
Vol 121 (S1) ◽  
pp. S18-S18
Author(s):  
T. Afanasyeva ◽  
V. Stepina ◽  
N. Belousova ◽  
T. Kondratyeva ◽  
E. Gurtsevitch
Keyword(s):  
Immune Response ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Terminal Protein ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma

mSphere ◽  
2020 ◽  
Vol 5 (6) ◽  
Author(s):  
Qian-Ying Zhu ◽  
Xiang-Wei Kong ◽  
Cong Sun ◽  
Shang-Hang Xie ◽  
Allan Hildesheim ◽  
...  
Keyword(s):  
Immune Response ◽  
Nasopharyngeal Carcinoma ◽  
Humoral Immune Response ◽  
Epstein Barr Virus ◽  
Healthy Controls ◽  
Humoral Immune ◽  
Barr Virus ◽  
Ebv Infection ◽  
Epstein Barr ◽  
Antibody Levels

ABSTRACT While Epstein-Barr virus (EBV) is the major cause of nasopharyngeal carcinoma (NPC), the value of the humoral immune response to EBV glycoproteins and NPC development remains unclear. Correlation between antiglycoprotein antibody levels, neutralization of EBV infectivity, and the risk of NPC requires systematic study. Here, we applied a cytometry-based method and enzyme-linked immunosorbent assay to measure neutralization of infectivity and antibody response to EBV glycoproteins (gH/gL, gB, gp350, and gp42) of plasma samples from 20 NPC cases and 20 high-risk and 20 low-risk healthy controls nested within a screening cohort in Sihui, southern China. We found that NPC cases have similar plasma neutralizing activity in both B cells and epithelial cells and EBV glycoprotein-specific IgA and IgG antibody levels compared with those of healthy controls. Significant correlations were observed between gH/gL IgG and gB IgG and the neutralizing ability against EBV infection of epithelial cells and B cells. These results indicate that a high level of glycoprotein antibodies may favor protection against primary EBV infection, instead of being low-risk biomarkers for NPC in long-term EBV-infected adults. In conclusion, this study provides novel insights into the humoral immune response to EBV infection and NPC development, providing valuable leads for future research that is important for prevention and treatment of EBV-related diseases. IMPORTANCE Epstein-Barr virus (EBV) is a human oncogenic gammaherpesvirus that infects over 90% of humans in the world and is causally associated with a spectrum of epithelial and B-cell malignancies such as nasopharyngeal carcinoma (NPC). A prophylactic vaccine against EBV is called for, but no approved vaccine is available yet. Therefore, EBV remains a major public health concern. To facilitate novel vaccines and therapeutics for NPC, it is of great importance to explore the impact of humoral immune response to EBV glycoproteins before the development of NPC. Therefore, in this study, we systematically assessed the correlation between antiglycoprotein antibody levels, neutralization of EBV infectivity, and the risk of NPC development. These results provide valuable information that will contribute to designing effective prevention and treatment strategies for EBV-related diseases such as NPC.

Sign in / Sign up

Export Citation Format

Share Document